<h1>Indian Government Approves Major Foreign Investments in Aurobindo Pharma and Glenmark, Boosting Make in India Initiative.</h1> The Cabinet Committee on Economic Affairs, led by the Prime Minister, approved significant foreign investments in Aurobindo Pharma Ltd. and Glenmark Pharmaceutical Ltd. Aurobindo Pharma will receive up to Rs. 2165 crore from Qualified Institutional Buyers, increasing its foreign institutional investor shareholding to 34.32%. Glenmark Pharmaceuticals raised its foreign investment limit from 35.07% to 49%, resulting in an inflow of about Rs. 2022 crore. Both companies, with a strong global presence, must continue producing essential medicines and maintain R&D expenditure levels. These investments highlight international confidence in India's pharmaceutical sector and support the government's Make in India initiative.